4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A single-domain antibody detects and neutralises toxic Aβ 42 oligomers in the Alzheimer’s disease CSF

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Amyloid-β 42 (Aβ 42) aggregation consists of a complex chain of nucleation events producing soluble oligomeric intermediates, which are considered the major neurotoxic agents in Alzheimer’s disease (AD). Cerebral lesions in the brain of AD patients start to develop 20 years before symptom onset; however, no preventive strategies, effective treatments, or specific and sensitive diagnostic tests to identify people with early-stage AD are currently available. In addition, the isolation and characterisation of neurotoxic Aβ 42 oligomers are particularly difficult because of their transient and heterogeneous nature. To overcome this challenge, a rationally designed method generated a single-domain antibody (sdAb), named DesAb-O, targeting Aβ 42 oligomers.

          Methods

          We investigated the ability of DesAb-O to selectively detect preformed Aβ 42 oligomers both in vitro and in cultured neuronal cells, by using dot-blot, ELISA immunoassay and super-resolution STED microscopy, and to counteract the toxicity induced by the oligomers, monitoring their interaction with neuronal membrane and the resulting mitochondrial impairment. We then applied this approach to CSF samples (CSFs) from AD patients as compared to age-matched control subjects.

          Results

          DesAb-O was found to selectively detect synthetic Aβ 42 oligomers both in vitro and in cultured cells, and to neutralise their associated neuronal dysfunction. DesAb-O can also identify Aβ 42 oligomers present in the CSFs of AD patients with respect to healthy individuals, and completely prevent cell dysfunction induced by the administration of CSFs to neuronal cells.

          Conclusions

          Taken together, our data indicate a promising method for the improvement of an early diagnosis of AD and for the generation of novel therapeutic approaches based on sdAbs for the treatment of AD and other devastating neurodegenerative conditions.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s13195-023-01361-z.

          Related collections

          Most cited references81

          • Record: found
          • Abstract: not found
          • Article: not found

          A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

            A tetrazolium salt has been used to develop a quantitative colorimetric assay for mammalian cell survival and proliferation. The assay detects living, but not dead cells and the signal generated is dependent on the degree of activation of the cells. This method can therefore be used to measure cytotoxicity, proliferation or activation. The results can be read on a multiwell scanning spectrophotometer (ELISA reader) and show a high degree of precision. No washing steps are used in the assay. The main advantages of the colorimetric assay are its rapidity and precision, and the lack of any radioisotope. We have used the assay to measure proliferative lymphokines, mitogen stimulations and complement-mediated lysis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

              Soluble oligomers are common to most amyloids and may represent the primary toxic species of amyloids, like the Abeta peptide in Alzheimer's disease (AD). Here we show that all of the soluble oligomers tested display a common conformation-dependent structure that is unique to soluble oligomers regardless of sequence. The in vitro toxicity of soluble oligomers is inhibited by oligomer-specific antibody. Soluble oligomers have a unique distribution in human AD brain that is distinct from fibrillar amyloid. These results indicate that different types of soluble amyloid oligomers have a common structure and suggest they share a common mechanism of toxicity.
                Bookmark

                Author and article information

                Contributors
                roberta.cascella@unifi.it
                Journal
                Alzheimers Res Ther
                Alzheimers Res Ther
                Alzheimer's Research & Therapy
                BioMed Central (London )
                1758-9193
                18 January 2024
                18 January 2024
                2024
                : 16
                : 13
                Affiliations
                [1 ]Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, ( https://ror.org/04jr1s763) Florence, Italy
                [2 ]Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, ( https://ror.org/041kmwe10) London, UK
                [3 ]Institute of Chemical Biology, Molecular Sciences Research Hub, Imperial College London, ( https://ror.org/041kmwe10) London, UK
                Article
                1361
                10.1186/s13195-023-01361-z
                10795411
                38238842
                625f2fa4-4de0-4bd1-9129-5531a92794e3
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 4 October 2023
                : 29 November 2023
                Categories
                Research
                Custom metadata
                © BioMed Central Ltd., part of Springer Nature 2024

                Neurology
                nanobodies,conformation-sensitive antibodies,amyloid β peptide,protein misfolding,early diagnosis,biofluids,aβ42-targeting therapy,neurodegenerative diseases

                Comments

                Comment on this article